← All diseases Brain and nervous system

Progressive supranuclear palsy (PSP)

Automatically tracked from PubMed and ClinicalTrials.gov, newest on top. Nothing ever disappears here: what you keep in your favorites remains findable. · RSS feed of this disease · only the strongest evidence

Search Period All yearsLast 12 monthsLast 5 years Topic All topicsGeneralNutrition and dietAlternative treatment methods Type of research Any type of researchHighest evidence only (31)Meta-analysis (11)Systematic review (13)Phase 3 study (4)Randomized Controlled Trial (3)Clinical trial (188)Review article (153)Early study (phase 1 or 2) (11)Single patient description (77)Laboratory or animal study (6)Commentary or Editorial (50) Studies currently recruiting participants only (32)

Filter

Publications and studies (1194)

• Frontotemporal dementia: does structural MRI-based clustering match clinical syndromes? (2026/05/05) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Progressive Supranuclear Palsy with Predominant Speech/Language Disorder. (2026/05/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Duloxetine for PSP-Related Speech Disorders. (2026/05/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Neurofilament light chain as a diagnostic and prognostic biomarker in atypical parkinsonisms: current evidence, new data, challenges, and future directions. (2026/05/01) ♡
• Between Habit and Mannerism: Idiosyncratic Motor Behavior. (2026/05/01) ♡
• Early Suspected Progressive Supranuclear Palsy-Cerebellar Type From MRI and Dopaminergic Imaging in a Patient Initially Presenting With Ataxia. (2026/05/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Cognitive and behavioral disturbances in PSP and MSA: clinical features and imaging correlates. (2026/05/01) ♡
• Cognitive impairment on the Alzheimer's Disease Centers' Uniform Data Set Version 3 Neuropsychological Test Battery in a Peruvian population with progressive supranuclear palsy. (2026/05/01) ♡
• Procerus sign as a diagnostic clue for progressive supranuclear palsy. (2026/05/01) ♡
• Cytoskeletal Imbalance and Axonal Vulnerability in Sporadic PSP-RS: Early Changes in a Human iPSC-Derived Neuronal Model with Altered mTOR Signaling. (2026/04/23) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. The Possible Significance of Proteomics in Understanding Molecular Mechanisms of Progressive Supranuclear Palsy, Corticobasal Degeneration, Multiple System Atrophy, and Dementia with Lewy Bodies. (2026/04/23) ♡
• A Short Version of Carers' Quality of Life Questionnaire for Parkinsonism: Data from Progressive Supranuclear Palsy Network. (2026/04/01) ♡
• Deep Learning-Based Brainstem Segmentation and Multi-Class Classification for Parkinsonian Syndrome. (2026/04/01) ♡
• Review articleiA summary of what is known about a topic, written by experts. Not compiled according to fixed search rules, so the selection of studies may be biased. Praja1 E3 ubiquitin ligase and the role it plays in neurodegeneration. (2026/04/01) ♡
• Distinctive magnetic resonance imaging features of progressive supranuclear palsy with cerebellar phenotype: hummingbird and Mickey Mouse signs. (2026/03/04) ♡
• A Hierarchical Etched Grid for Correlative Chemical Imaging. (2026/03/04) ♡
• 18 F-FDG, 18 F-FP-CIT, and 18 F-Florzolotau PET Imaging in Progressive Supranuclear Palsy : Region-Specific Correlations Between Glucose Metabolism, Dopaminergic Function, and Tau Pathology. (2026/03/01) ♡
• Utility of Locus Coeruleus Signal Intensity on High-resolution T1-weighted MR Imaging with Magnetization Transfer for Differentiating Parkinson's Disease from Atypical Parkinsonism. (2026/02/26) ♡
• Visual interpretation of [(18)F]Florzolotau Tau-PET imaging for differentiating Alzheimer's disease and progressive supranuclear palsy. (2026/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Comparing and combining TSPO-PET tracers in tauopathies. (2026/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Barcelona Progressive Supranuclear Palsy (PSP) Registry: Clinical, Oculomotor, and Cerebrospinal Fluid Markers; from Suggestive to Definite Cases. (2026/02/01) ♡
• Spatial Metabolic Covariance Networks in Progressive Supranuclear Palsy: Implications for Symptomatology and Their Neural Basis. (2026/02/01) ♡
• Hybrid Tau-PET/MRI study: Quantitative susceptibility mapping in progressive supranuclear palsy and its correlation with Tau-PET. (2026/02/01) ♡
• Randomized researchiParticipants were divided into groups by lottery and compared with each other. This reduces the chance that a difference is due to something other than the treatment. Safety, Tolerability, Pharmacokinetics, and Brain Target Occupancy of the OGA Inhibitor ASN90 in Healthy Participants. (2026/02/01) ♡
• Backward walking as a mobility assessment and exercise intervention for persons with neurologic disorders: A scoping review. (2026/02/01) ♡
• White matter hyperintensities in the deep cerebral venous territory differ between subcortical and cortical 4-repeat tauopathies. (2026/02/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Percutaneous endoscopic gastrostomy in atypical parkinsonian syndromes: survival and aspiration outcomes from a retrospective international cohort. (2026/01/30) ♡
• Plasma pTau217 and Neurofilament Light Chain as Differentiative Markers for Progressive Supranuclear Palsy From Parkinson Disease. (2026/01/13) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Rapidly progressive dysphagia and vertical supranuclear gaze palsy: a key diagnostic clue for progressive supranuclear palsy in Levodopa-Resistant parkinsonism. (2026/01/13) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Wernicke's encephalopathy unmasking progressive supranuclear palsy and Alzheimer's pathology: a diagnostic challenge in an older adult. (2026/01/06) ♡
• A Biomarker-Based Classification of Corticobasal Syndrome. (2026/01/01) ♡
• Description of individual patientsiThe story of one or a couple of patients. Informative, but you cannot infer from it whether something works in general. Absence of STN Neuronal Activity during MER in DBS Surgery: Diagnostic and Clinical Implications. (2026/01/01) ♡
• A Mathematical Model of Cellular Aggregation Predicts Patterns of Tau Accumulation in Neurodegenerative Disease. (2026/01/01) ♡
• Proximity Labeling of the Tau Repeat Domain Enriches RNA-Binding Proteins That Are Altered in Alzheimer's Disease and Related Tauopathies. (2026/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Utility of Progression Rate Since Symptom Onset in Predicting Subsequent Survival in Progressive Supranuclear Palsy. (2026/01/01) ♡
• Commentary or editorialiAn expert's opinion or commentary, not new research. Reply to: Utility of Progression Rate Since Symptom Onset in Predicting Subsequent Survival in Progressive Supranuclear Palsy. (2026/01/01) ♡
• Interpeduncular Angle: A Possible Marker to Differentiate Atypical Parkinsonism from Idiopathic Parkinson's Disease. (2026/01/01) ♡
• ERBB4 colocalizes with phosphorylated tau aggregates in multiple tauopathies. (2026/01/01) ♡
• Progressive Supranuclear Palsy or Something More? Unveiling Late-Onset Wilson's Disease. (2026/01/01) ♡
• Comparative [18F]Florzolotau and [18F]FDG PET Imaging Patterns in Anti-IgLON5 Disease and Progressive Supranuclear Palsy. (2026/01/01) ♡
• PET evaluation of cholinergic system differences in progressive supranuclear palsy and age-matched controls using [(18)F]VAT. (2026/01/01) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Sociodemographic Factors and Criminal Behaviour Preceding Neurodegenerative Disease - Retrospective Register Study (2026-08-10) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia (2026-08-07) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Art Therapy in Progressive Supranuclear Palsy (2026-08-06) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. The Progressive Supranuclear Palsy Clinical Trial Platform (2026-08-05) ♡
• Early-stage study (phase 1 or 2)iEarly research in a small group, primarily aimed at safety and dosage. Whether it actually works still needs to be determined afterward. A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy (2026-08-03) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Automated Imaging Differentiation of Parkinsonism (2026-07-31) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) (2026-07-30) ♡
• Clinical trialiResearch in patients, without randomization between groups. Useful, but less certain than a randomized trial. Remote Monitoring in Progressive Supranuclear Palsy (PSP) (2026-07-29) ♡
• Phase 3 studyiResearch in a large group of patients, the final step before a treatment can be approved. What comes out here carries significant weight. A Study to Evaluate the Efficacy of NIO752 in Participants With Progressive Supranuclear Palsy (2026-07-29) ♡

↑ Back to top

codex.care does not provide medical advice. Always discuss symptoms, medication, and treatment choices with your own healthcare provider.